Clinical Trial Update: Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study of Prolarix in hepatocellular carcinoma was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Prolarix

Snippet

Sponsor: BTG International Inc. | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-06-09